Navigating Delaware’s Research and Development Tax Credit: The Immutable September 15th Filing Deadline

I. Executive Summary: The Critical Nature of the September 15th Deadline

The September 15th filing deadline is the mandatory cutoff for submitting the necessary application to qualify for the Delaware Research and Development (R&D) Tax Credit. This procedural requirement serves as the immutable gateway for securing the credit, and failure to comply results in the forfeiture of the benefit for the taxable year.

This critical compliance date requires proactive tax planning and cannot be overlooked. Unlike the main corporate income tax return, which often benefits from extensions, the R&D application deadline is fixed, ensuring timely submission for access to this highly valuable, potentially refundable state credit.

Introduction to the Delaware R&D Tax Credit Program

The State of Delaware maintains a robust R&D Tax Credit program designed to stimulate innovation and support economic expansion within the state. This credit is formally codified under Title 30, Chapter 20, Subchapter VIII, $\S 2070$ of the Delaware Code.1

The Delaware credit program is largely modeled after its federal counterpart under Internal Revenue Code (IRC) $\S 41$.3 Consequently, R&D activities conducted within Delaware that qualify for the federal credit automatically qualify for the state credit.3

Several features make the Delaware R&D credit particularly attractive to businesses:

• Refundability: Crucially, unused tax credits are refundable, meaning the state pays the unused credit amount to the taxpayer as a tax refund.4 This provides a significant cash flow benefit, especially for emerging technology companies that may be in a Net Operating Loss (NOL) position. Furthermore, since January 1, 2017, the credit is no longer subject to a total cap on the credits issued by the State of Delaware.5
• Enhanced Small Business Rates: The program provides significantly higher credit percentages for “small businesses,” defined as any taxpayer with average annual gross receipts of $20 million or less.1

II. The Paramount Importance of the September 15th Compliance Deadline

The September 15th date is the singular most important filing requirement for securing the Delaware R&D credit, overriding general assumptions about tax return timelines.

Meaning of the Filing Deadline: The Application Gatekeeper

The September 15th deadline dictates the submission timeline for the required application form: Delaware Form 2070AC or Form 2071AC (Application and Computation Schedule for Claiming Delaware Research and Development Tax Credits).5

Guidance issued by the Delaware Division of Revenue emphasizes the strict timing:

“FORM 2070AC MUST BE COMPLETED AND SUBMITTED ON OR BEFORE SEPTEMBER 15TH AFTER THE END OF THE TAXABLE YEAR DURING WHICH THE QUALIFIED RESEARCH & DEVELOPMENT EXPENSES WERE MADE.” 5

For a business operating on a calendar year (ending December 31st), this means the application for the prior year’s expenses must be filed by September 15th of the current year. This mandate establishes the date as a hard, procedural requirement for credit qualification.

The Compliance Trap: Distinction from the Corporate Return Due Date

A common procedural misstep occurs when taxpayers mistakenly equate the R&D credit application deadline with the deadline for filing the primary corporate income tax return.

For a calendar year C-Corporation, the Delaware corporate income tax return (Form 1100) is typically due on April 15th. If an extension is filed, the final extended due date is generally October 15th.7 However, the Form 2070AC/2071AC application is due a full month earlier, on September 15th.5

The significance of this timing discrepancy is profound. Even if a company files an extension for its main corporate return until October 15th, believing all associated tax filings are covered, they will have already missed the window to apply for the R&D credit. Because the Division of Revenue treats the Form 2070AC/2071AC as a required application for pre-approval and eligibility, failure to submit it by September 15th voids the opportunity to claim the credit for that tax year. This structure confirms that the September 15th date is an immutable prerequisite for accessing the benefit.

Consequences of Missing the Application Deadline

While taxpayers are subject to general penalties for late payments or failure to file main returns—including a $200 late fee and 1.5% monthly interest on unpaid taxes 9—the failure to meet the September 15th R&D application deadline carries a far more significant strategic consequence.

The Division of Revenue’s documentation frames Form 2070AC/2071AC as a necessary qualification step.4 If this qualification criterion is not met, the entire potential credit benefit is lost. For companies heavily investing in R&D, this can mean forfeiting a refundable credit that amounts to hundreds of thousands of dollars, resulting in a substantial and immediate loss of available working capital, dwarfing any standard administrative late fee. The true consequence is the outright loss of the tax preference itself.

III. Delaware Division of Revenue Guidance and Procedural Requirements

Successful compliance demands that taxpayers follow a defined, sequential flow mandated by the Delaware Division of Revenue, starting with the timely application.

Compliance Flow: Pre-Approval and Transfer Process

The claiming process for the Delaware R&D credit is executed in three distinct stages:

1. Application and Computation: The taxpayer completes Form 2070AC or 2071AC, detailing their chosen credit calculation method (Method A or B), and ensures submission to the Division of Revenue on or before September 15th after the close of the taxable year.5
2. Approval: The Division of Revenue reviews the application and officially approves the calculated credit amount.
3. Claiming and Reporting: The approved credit amount, derived from Form 2070AC/2071AC, is then transferred to Delaware Form 700, Delaware Income Tax Credit Schedule.8 Both Form 700 and the approved application form must be attached to the taxpayer’s annual Delaware income tax return (e.g., Form 1100).8

Mandatory Documentation: The Federal Form 6765 Link

Given that the Delaware credit is based on the federal definition of qualified research expenses, the application requires clear documentation of the federal claim. The state application form explicitly instructs taxpayers to ATTACH A COPY OF FEDERAL FORM 6765 to the submission.5

This federal linkage creates a challenging internal timeline for taxpayers. Since Federal Form 6765 contains the comprehensive documentation and computation for the federal R&D tax credit (including QREs and base calculations), the September 15th state application deadline effectively requires the finalization of the entire federal R&D study and its supporting documentation many weeks or even months before the federal return itself is due. This necessity imposes a strict completion deadline on internal R&D and tax departments.

For taxpayers who are part of a larger consolidated federal corporate group, the documentation requirements are even more rigorous. They must attach a pro forma Form 6765 that details the R&D expenses and calculation specific to the corporate applicant filing in Delaware.6

Reporting for Refundability

The mechanism for claiming the credit confirms its refundable nature. For C-Corporations filing Form 1100, the approved refundable credit amount derived from Form 700 is recorded on Line 19, “Approved Refundable Income Tax Credits”.11 This procedural placement ensures that the credit is treated as a payment, which, when it exceeds the corporate tax liability, results in a refund.4

Pass-Through Entities (S-Corps and Partnerships)

The September 15th deadline applies equally to S Corporations and Partnerships seeking the credit. These entities must file the appropriate application form (Form 2071AC) by the deadline to compute and secure the approved credit.5

While the credit is computed at the entity level, it is designed to be passed through to the owners. Once approved, the credit is allocated to shareholders or partners based on their respective ownership percentages.5 The allocated credits are subsequently reported on Delaware Form 700 (specifically Line 10(b) for S-Corps and Line 10(c) for Partnerships).5

A delay in the entity-level filing of Form 2071AC and subsequent Division of Revenue approval directly impacts the ability of individual owners to timely claim their allocated portion of the refundable credit. Therefore, the September 15th deadline is critical not just for the entity, but for the personal compliance of its owners.

IV. Mechanics of Credit Calculation and Maximization

Prior to the September 15th deadline, taxpayers must make a critical strategic choice regarding their credit calculation methodology. Delaware Code $\S 2070(a)(1)$ provides two options, and the taxpayer’s election is an annual choice, independent of the method used for the federal credit.1 Tax planning should involve modeling both methods to maximize the benefit.

Method A: The Incremental Research Credit

This method calculates the credit based on the excess of current-year Qualified Research Expenses (QREs) over a historical “base amount.” It is often advantageous for businesses with stable and consistently growing R&D investment.12

• Calculation Structure: Credit = Percentage $\times$ (Delaware QREs – Delaware Base Amount).3
• Base Amount Complexity: Calculating the Delaware Base Amount requires gathering historical QRE and gross receipt data from the four preceding taxable years to establish the Delaware Fixed Based Percentage (DFBP).5
• Credit Rates: The rate is 10% under the general rule, increasing significantly to 20% for small businesses.1

Method B: Alternative Simplified Credit (ASC) Apportionment

Method B is generally preferred by companies with fluctuating R&D expenditures or those with limited historical data.12 It relies on the federal ASC methodology established under IRC $\S 41(c)(5)$.1

• Calculation Structure: The total federal ASC is determined first, and then Delaware’s share is calculated by multiplying the federal credit by the ratio of Delaware QREs to total (all states) QREs.1
• Credit Rates: The standard rate is 50% of Delaware’s apportioned share of the federal ASC. This rate is amplified to 100% for small businesses.1

The necessity to file the application by September 15th ensures that taxpayers must conduct comparative analysis and calculation optimization for both Method A and Method B well in advance. For small businesses, the 100% rate offered by Method B often results in the highest achievable credit.12 This critical strategic choice is officially locked in upon the timely submission of Form 2070AC/2071AC.

Comparison of Delaware R&D Credit Calculation Methods

The following table summarizes the key components of the two available calculation methods, which must be modeled before the deadline:

Table 1: Comparison of Delaware R&D Credit Calculation Methods

V. Case Study: Timely Filing and Refundability

The following scenario illustrates the operational necessity of the September 15th deadline for maximizing the refundable credit benefit.

Scenario: BioTech Innovations Inc. (Small Business)

• Entity Type: C-Corporation, qualifying as a small business with average annual gross receipts below the $20 million threshold.1
• Tax Year End: December 31, 2024.
• Required Compliance Date: September 15, 2025.
• Tax Status: BioTech Innovations Inc. generated a large Net Operating Loss (NOL) in 2024 and expects a zero tax liability for Delaware corporate income tax.
• Financial Data (2024):

• Current Year DE QREs: $1,500,000.
• Pre-calculated DE Base Amount (Method A): $800,000.12
• Pre-calculated DE Apportioned Federal ASC (Method B): $150,000.

Calculation and Optimization

Before the September deadline, BioTech Innovations Inc. computes the credit under both methods:

1. Method A (20% Small Business Rate):
   $(\$1,500,000 \text{ QREs} – \$800,000 \text{ Base}) \times 20\% = \$700,000 \times 20\% = \mathbf{\$140,000}$
2. Method B (100% Small Business Rate):
   $\$150,000 \text{ Apportioned ASC} \times 100\% = \mathbf{\$150,000}$

BioTech Innovations Inc. elects Method B, securing a $150,000 Delaware R&D credit.

The Impact of the Deadline on Cash Flow

Timely Filing (Actionable Success):

BioTech Innovations Inc. submits Form 2070AC, electing Method B, and attaches its finalized Federal Form 6765 documentation on September 1, 2025. This action meets the mandatory deadline. Following approval, the company files its Form 1100 by the extended October 15, 2025 deadline. Since the company had a $0 tax liability, the $150,000 approved credit is listed on Form 700 and transferred to Line 19 of Form 1100 as an Approved Refundable Income Tax Credit.11 The result is that the company receives a direct tax refund check for $150,000, bolstering working capital for future research.

Missed Deadline (Failure Scenario):

If BioTech Innovations Inc. fails to file Form 2070AC by September 15, 2025, the application is deemed late and rejected by the Division of Revenue, regardless of the corporation’s extended return due date of October 15th. The company loses all eligibility for the $150,000 refundable credit for the 2024 tax year. The financial consequence of this procedural lapse is a direct cash loss equivalent to the value of the credit.

VI. Conclusion and Actionable Recommendations

The Delaware R&D tax credit is a highly beneficial incentive, particularly due to its refundable nature and enhanced rates for small businesses. However, the realization of this benefit is entirely conditional upon strict compliance with specific procedural timing.

The September 15th deadline for submitting the Application and Computation Schedule (Form 2070AC/2071AC) is a non-negotiable gateway. Tax professionals must recognize that this date operates independently of, and often precedes, the final due date for the main corporate income tax return. Compliance efforts must therefore focus on securing application approval by this date, making it the most critical hard deadline in the annual R&D credit cycle.

Actionable Recommendations for Compliance Teams:

1. Prioritize the September 15th Deadline: Compliance teams must incorporate the Form 2070AC/2071AC filing date into the corporate tax calendar as an unextendable procedural requirement, ensuring it is treated with higher priority than the primary income tax return filing date.6
2. Advance Federal Documentation Completion: Because the Delaware application requires the finalized Federal Form 6765, internal workflows must be structured to finalize the entire federal R&D study, including QRE determination and calculation, no later than mid-August. This preparation allows sufficient time for Method optimization modeling and internal review prior to the September 15th state submission.6
3. Conduct Annual Optimization Modeling: Before submission, the taxpayer must perform comparative modeling of both the Incremental Credit (Method A) and the ASC Apportionment (Method B) to determine which method maximizes the benefit. This determination is an annual election and must be finalized upon the September 15th application filing.1
4. Ensure Timely Pass-Through Entity Filing: For S Corporations and Partnerships, timely filing of Form 2071AC is essential to secure entity-level approval. Delays in this process directly hinder the ability of individual shareholders and partners to receive their allocated, refundable credits in a timely manner against their personal Delaware income tax liabilities.5

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/